Brought to you by 
Grail Bio spins out of Illumina, raises over $100mm through Series A round
12 Jan 2016
Executive Summary
Illumina Inc. spun out a new cancer testing company Grail Bio and participated in the company's Series A round of over $100mm. (Arch Venture Partners, Bezos Expeditions, Bill Gates, and Sutter Hill Ventures also took part in the financing.)
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Grail Bio spins out of Illumina, raises over $100mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice